MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Key Stats

• Today's Range: $8.58 to $9.48
• 50-Day Range: $8.63 to $16.28
• 52-Week Range: $8.54 to $27.50
• Volume: 159,770 shs
• Average Volume: 224,523 shs
• Market Capitalization: $290.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Buy

MBX Biosciences Stock Analysis - MarketRank™

MBX Biosciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 811th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MBX Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MBX Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MBX Biosciences are expected to grow in the coming year, from ($13.25) to ($2.30) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MBX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MBX Biosciences does not currently pay a dividend.

Dividend Growth

MBX Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MBX.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

MBX Biosciences has a news sentiment score of -0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for MBX Biosciences this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, MBX Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,555,308.00 in company stock and sold $0.00 in company stock.

MBX Stock Analysis - Frequently Asked Questions

How have MBX shares performed this year?

MBX Biosciences' stock was trading at $18.43 at the beginning of the year. Since then, MBX stock has decreased by 52.8% and is now trading at $8.70.
View the best growth stocks for 2025 here.

How were MBX Biosciences' earnings last quarter?

MBX Biosciences, Inc. (NYSE:MBX) posted its earnings results on Thursday, November, 7th. The company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($2.72) by $0.06.

When did MBX Biosciences IPO?

MBX Biosciences (MBX) raised $163 million in an IPO on Friday, September 13th 2024. The company issued 10,200,000 shares at $16.00 per share.

When did MBX Biosciences' lock-up period expire?

MBX Biosciences' lock-up period expired on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its initial public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Who are MBX Biosciences' major shareholders?

Top institutional investors of MBX Biosciences include Wellington Management Group LLP (8.71%), Driehaus Capital Management LLC (4.73%), Price T Rowe Associates Inc. MD (3.48%) and Woodline Partners LP (1.82%). Insiders that own company stock include Life Sciences X LP Frazier, Edward T Mathers and P Kent Hawryluk.
View institutional ownership trends.

How do I buy shares of MBX Biosciences?

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MBX Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 3/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MBX
• Previous Symbol: NYSE:MBX
• CIK: 1776111
• Web: mbxbio.com
• Phone: (317) 659-0200
• Fax: N/A
• Employees: 36
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $37.25
• High Stock Price Target: $44.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +328.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,417,000
• Free Float: N/A
• Market Cap: $290.73 million
• Optionable: N/A
• Beta: N/A